New radioactive drug enters human testing for Hard-to-Treat tumors
Disease control
Not yet recruiting
This is the first human study of an experimental radioactive drug called RYZ401 for people with advanced neuroendocrine tumors and other solid tumors that have a specific marker. The main goals are to find the safest and most effective dose, check for side effects, and see if the…
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC